The Peptide Directory

Peptide Dose Reference: Labels & Trials Only

Last updated

Doses as printed in FDA labels or used in published trials for 10 peptides, with sources. Where no approved or studied human dose exists, we say so. Not advice.

Semaglutide

FDA-approved (Ozempic, Wegovy, Rybelsus); higher-dose Wegovy HD 7.2 mg approved March 19, 2026.

Wegovy label (weight)Escalation 0.25 → 0.5 → 1 → 1.7 → 2.4 mg once weekly, each step 4 weeks; 2.4 mg maintenance (1.7 mg if needed).
Wegovy HD (label, 2026)7.2 mg once weekly, only after at least 4 weeks at 2.4 mg when more weight loss is clinically indicated.
STEP 1 trial2.4 mg once weekly for 68 weeks.

Tirzepatide

FDA-approved (Mounjaro for type 2 diabetes; Zepbound for weight management and obstructive sleep apnea with obesity).

Zepbound label (weight)Start 2.5 mg once weekly for 4 weeks, then 5 mg; increase in 2.5 mg steps after at least 4 weeks on the current dose. Maintenance 5, 10 or 15 mg; maximum 15 mg weekly.
Zepbound label (OSA)Maintenance 10 mg or 15 mg once weekly.
SURMOUNT-1 trial5, 10 or 15 mg once weekly for 72 weeks.

Retatrutide

Investigational — not FDA-approved. Lilly plans a US Biologics License Application in Q1 2027.

TRIUMPH-2 / TRIUMPH-3 designStart 2 mg weekly; step up every 4 weeks (2 → 4 → 6 → 9 → 12 mg) to target doses of 4, 9 or 12 mg.
Phase 2 (2023)Doses from 1 mg to 12 mg weekly over 48 weeks.

BPC-157

Not FDA-approved. FDA advisers voted 8–6 (1 abstention) on July 23, 2026 to recommend it for the 503A bulks list; FDA has not acted.

Human doseThere is no established or approved human dose. Pilot studies used single protocols in very small groups and do not establish a dose.

TB-500

Not FDA-approved. Included in the July 23, 2026 advisory vote (8–6) recommending 503A compounding; FDA has not acted.

Human doseNo established or approved human dose exists for TB-500.

GHK-Cu

Not FDA-approved as a drug; widely used as a cosmetic ingredient in topical products.

Human doseNo approved injectable dose exists. Cosmetic products use varying topical concentrations.

Ipamorelin

Not FDA-approved.

Human doseNo established or approved human dose exists.

Sermorelin

Previously FDA-approved as Geref for pediatric growth hormone deficiency; the brand product was discontinued.

Adult doseThere is no current FDA-approved adult dose.

Tesamorelin

FDA-approved (Egrifta) to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

LabelDosing for the approved indication is set in the Egrifta prescribing information; we do not restate it as general guidance.

MOTS-c

Not FDA-approved. FDA advisers voted 7–5 (2 abstentions) in July 2026 to recommend 503A compounding; FDA has not acted.

Human doseNo established or approved human dose exists.

Converting mg, mL and units

Use the units converter and the reconstitution calculator — arithmetic only.

Frequently asked questions

Why don't you list doses for BPC-157 or TB-500?

No FDA label or adequate human trial establishes a dose for them. Publishing community ranges would amount to dosing advice for unapproved substances.

Where do the doses on this page come from?

Only from FDA prescribing information or the published designs of clinical trials, linked on each peptide profile.

Can I use these doses?

No — they are reference information. Dosing is decided by a licensed prescriber for an approved product.

Find a clinic

Our clinic directory lists only clinics whose address and services we confirmed on their own websites, with the date we checked.

Browse the clinic directory